The Epigenetic Landscape in the Treatment of Gynecologic Malignancies.

@article{Eskander2018TheEL,
  title={The Epigenetic Landscape in the Treatment of Gynecologic Malignancies.},
  author={Ramez N. Eskander},
  journal={American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting},
  year={2018},
  volume={38},
  pages={
          480-487
        }
}
  • R. Eskander
  • Published 23 May 2018
  • Medicine, Biology
  • American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
The care of patients with advanced-stage or recurrent endometrial, ovarian, and cervical cancer remains clinically challenging. Despite the identification of novel therapeutics and advancements in supportive care, survival outcomes have been relatively unchanged over the past decade. In addition to established genomic alterations and the contributions of the tumor microenvironment to cancer progression, epigenetic mechanisms have emerged as important contributors to gynecologic cancer… 

Tables from this paper

Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer

TLDR
The aim of this review is to shed light into the current state and future prospects of small-molecule inhibitors on EC treatment by summarizing the extensive number of clinical trials that have been performed during the last years, and to provide a comprehensive up-to-date document with the most remarkable results.

Epigenetic Dysregulation at the Crossroad of Women’s Cancer

TLDR
The broad principles of epigenetic regulation of DNA methylation and demethylation, histone acetylation and deacetylation, and RNA methylation in women's cancers in the context of gene expression, hormonal action, and the EGFR family of cell surface receptor tyrosine kinases are discussed.

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

TLDR
The GYNOCARE, COST Action CA18117 (European Network for Gynecological Rare Cancer Research) programme aims to address challenges through the creation of a unique network between key stakeholders covering distinct domains from concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal and regulatory requirements for international innovative clinical trials.

Intersectionality Between Epigenetics and Cancer Health Disparities Stemming from Social Determinants of Health (SDoH) Through a Gynecologic Oncology Lens: A Narrative Review.

TLDR
A narrative review exposes existing gaps in evidence and provides recommendations of future preventive efforts that can target the mitigation of gynecologic cancer disparities.

Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior

TLDR
Differences in DNA methylation identified numerous genes that could serve as potential biomarkers and/or therapeutic targets in HGSOC, including RAS as well as hippo signaling in normal vs primary H GSOC.

Epigallocatechin gallate inhibits cell growth and regulates miRNA expression in cervical carcinoma cell lines infected with different high-risk human papillomavirus subtypes

TLDR
It is suggested that EGCG suppresses cervical carcinoma cell growth, possibly via regulating the expression of miRs, suggesting their potential as therapeutic targets for the control and prevention of cervical cancer.

References

SHOWING 1-10 OF 90 REFERENCES

Epigenetics and cervical cancer: from pathogenesis to therapy

TLDR
The recent progress of epigenetic study for cervical cancer research is reviewed including role of these epigenetic changes in disease progression, their prognostic values, and their use in targeted therapy.

The roles of ARID1A in gynecologic cancer

  • T. MaoI. Shih
  • Biology, Medicine
    Journal of gynecologic oncology
  • 2013
TLDR
This review will summarize the recent advances in studying the roles of ARID1A mutations in gynecologic cancers with special emphasis on how this new knowledge will further extend the understanding of the pathogenesis of endometrium-related carcinomas.

Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.

TLDR
This prospective, randomized, Phase III clinical trial explored the impact of adding the antiangiogenic agent bevacizumab to two separate cytotoxic chemotherapy backbones and met its primary end point, showing a survival advantage of approximately 4 months without detriment in quality of life.

Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer

TLDR
In an era of biologics, combined therapy with cytotoxic drugs and molecular targeted agents, as well as the use of nonplatinum doublets, represent an exciting area yet to be fully explored.

Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer

TLDR
In an era of biologics, combined therapy with cytotoxic drugs and molecular targeted agents, represents an exciting arena yet to be fully explored.

Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review).

TLDR
It is now evident that aberrant hypermethylation inactivates cancer-related genes including those associated with cell cycle control, apoptosis, and DNA repair, which opens up approaches to prevention, diagnosis, risk assessment, and treatment of type I endometrial cancer.

Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target

TLDR
Targeting PRKCI by small molecule inhibitor, sodium aurothiomalate (ATM), significantly reduced the in vivo tumor growth and may be a new therapeutic strategy to improve the treatment of CCOC.

Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data

TLDR
Different methylation profiles occur in the three types of gynecologic cancer, indicating the potential role of DNA methylation as marker for cancer management.

Targeting angiogenesis in advanced cervical cancer

TLDR
The first prospective phase III clinical trial exploring the anti-angiogenic agent, bevacizumab, was published, meeting its primary endpoint, with a significant improvement in overall survival.
...